Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

266 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies.
Kuno T, Claessen B, Cao D, Chandiramani R, Guedeney P, Sorrentino S, Krucoff M, Kozuma K, Ge J, Seth A, Makkar R, Bangalore S, Bhatt DL, Angiolillo DJ, Saito S, Neumann FJ, Hermiller J, Rau V, Ruster K, Wang J, Valgimigli M, Mehran R. Kuno T, et al. Among authors: hermiller j. J Thromb Thrombolysis. 2021 Aug;52(2):419-428. doi: 10.1007/s11239-020-02321-2. Epub 2021 Mar 11. J Thromb Thrombolysis. 2021. PMID: 33709255
Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
Jonas M, Stone GW, Mehran R, Hermiller J, Feldman R, Herrmann HC, Cox DA, Kuntz RE, Popma JJ, Rogers C; FilterWire EX Randomized Evalulation (FIRE) Investigators. Jonas M, et al. Among authors: hermiller j. Eur Heart J. 2006 Apr;27(8):920-8. doi: 10.1093/eurheartj/ehi736. Epub 2006 Jan 16. Eur Heart J. 2006. PMID: 16415300 Clinical Trial.
Six-month outcomes after percutaneous intervention for lesions in aortocoronary saphenous vein grafts using distal protection devices: results from the FIRE trial.
Halkin A, Masud AZ, Rogers C, Hermiller J, Feldman R, Hall P, Haber RH, Cambier PA, Caputo RP, Turco M, Kovach R, Brodie B, Herrmann HC, Kuntz RE, Popma JJ, Ramee S, Cox DA, Mehran R, Stone GW. Halkin A, et al. Among authors: hermiller j. Am Heart J. 2006 Apr;151(4):915.e1-7. doi: 10.1016/j.ahj.2005.09.018. Am Heart J. 2006. PMID: 16569562 Clinical Trial.
A novel bioresorbable polymer paclitaxel-eluting stent for the treatment of single and multivessel coronary disease: primary results of the COSTAR (Cobalt Chromium Stent With Antiproliferative for Restenosis) II study.
Krucoff MW, Kereiakes DJ, Petersen JL, Mehran R, Hasselblad V, Lansky AJ, Fitzgerald PJ, Garg J, Turco MA, Simonton CA 3rd, Verheye S, Dubois CL, Gammon R, Batchelor WB, O'Shaughnessy CD, Hermiller JB Jr, Schofer J, Buchbinder M, Wijns W; COSTAR II Investigators Group. Krucoff MW, et al. Among authors: hermiller jb jr. J Am Coll Cardiol. 2008 Apr 22;51(16):1543-52. doi: 10.1016/j.jacc.2008.01.020. J Am Coll Cardiol. 2008. PMID: 18420096 Free article. Clinical Trial.
A pooled gender based analysis comparing the XIENCE V(R) everolimus-eluting stent and the TAXUS paclitaxel-eluting stent in male and female patients with coronary artery disease, results of the SPIRIT II and SPIRIT III studies: two-year analysis.
Seth A, Serruys PW, Lansky A, Hermiller J, Onuma Y, Miquel-Hebert K, Yu S, Veldhof S, Sood P, Sudhir K, Stone GW. Seth A, et al. Among authors: hermiller j. EuroIntervention. 2010 Feb;5(7):788-94. doi: 10.4244/eijv5i7a132. EuroIntervention. 2010. PMID: 20142192
A new era of prospective real-world safety evaluation primary report of XIENCE V USA (XIENCE V Everolimus Eluting Coronary Stent System condition-of-approval post-market study).
Krucoff MW, Rutledge DR, Gruberg L, Jonnavithula L, Katopodis JN, Lombardi W, Mao VW, Sharma SK, Simonton CA, Tamboli HP, Wang J, Wilburn O, Zhao W, Sudhir K, Hermiller JB. Krucoff MW, et al. Among authors: hermiller jb. JACC Cardiovasc Interv. 2011 Dec;4(12):1298-309. doi: 10.1016/j.jcin.2011.08.010. JACC Cardiovasc Interv. 2011. PMID: 22192371 Free article.
Contemporary incidence and predictors of stent thrombosis and other major adverse cardiac events in the year after XIENCE V implantation: results from the 8,061-patient XIENCE V United States study.
Naidu SS, Krucoff MW, Rutledge DR, Mao VW, Zhao W, Zheng Q, Wilburn O, Sudhir K, Simonton C, Hermiller JB. Naidu SS, et al. JACC Cardiovasc Interv. 2012 Jun;5(6):626-35. doi: 10.1016/j.jcin.2012.02.014. JACC Cardiovasc Interv. 2012. PMID: 22721657 Free article.
Sustained low clinical event rates in real-world patients receiving everolimus-eluting coronary stent system from a large, prospective, condition of approval study: 2-year clinical outcomes from the XIENCE V USA Study.
Hermiller JB, Rutledge DR, Gruberg L, Katopodis JN, Lombardi W, Mao VW, Zhao W, Sharma SK, Tamboli HP, Wang J, Jonnavithula L, Sudhir K, Krucoff MW. Hermiller JB, et al. J Interv Cardiol. 2012 Dec;25(6):565-75. doi: 10.1111/j.1540-8183.2012.00766.x. Epub 2012 Sep 23. J Interv Cardiol. 2012. PMID: 22998355 Free article. Clinical Trial.
266 results